NDA 209830 · Alkermes INC
Aristada Initio Kit
Aripiprazole Lauroxil · Intramuscular
Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jun 29, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8
2 Phase 3, 0 recruiting
FAERS reports
402
109 serious, 6 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ARISTADA INITIO is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ( 5.1 ) ARISTADA INITIO is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 )
What it is approved for
From the label in effect Jan 28, 2025.
ARISTADA INITIO, in combination with oral aripiprazole, is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults. ARISTADA INITIO, in combination with oral aripiprazole, is indicated for the initiation of ARISTADA ® when used for the treatment of schizophrenia in adults ( 1 ).
Mechanism: Aripiprazole lauroxil is a prodrug of aripiprazole. Following intramuscular injection, aripiprazole lauroxil is likely converted by enzyme-mediated hydrolysis to N -hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. The mechanism of action of aripiprazole in schizophrenia is unclear. However, efficacy could be mediated through a combination of partial agonist activity at dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ARISTADA INITIO KIT · ARIPIPRAZOLE LAUROXIL 675MG/2.4ML (281.25MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Aripiprazole Lauroxil" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With SchizophreniaPivotal-lookingCompleted
Alkermes, Inc.Industry
NCT01469039 · 623 participants · Start Dec 2011 · Primary completion Jan 2014
Drug: ALKS 9072; Placebo · For: Schizophrenia
Sites: Little Rock, Arkansas; Springdale, Arkansas; Cerritos, California · 84 sites in all
- A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of SchizophreniaPivotal-lookingCompleted
Alkermes, Inc.Industry
NCT03345979 · 200 participants · Start Nov 15, 2017 · Primary completion Mar 12, 2019
Drug: Paliperidone Palmitate · For: Schizophrenia
Sites: Little Rock, Arkansas; Rogers, Arkansas; Cerritos, California · 16 sites in all
- An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable SchizophreniaPivotal-lookingCompleted
Alkermes, Inc.Industry
NCT02320032 · 140 participants · Start Dec 2014 · Primary completion Apr 2016
Drug: Aripiprazole Lauroxil · For: Schizophrenia
Sites: Little Rock, Arkansas; Cerritos, California; Garden Grove, California · 16 sites in all
- A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With SchizophreniaCompleted
Alkermes, Inc.Industry
NCT02634320 · 51 participants · Start Dec 2015 · Primary completion Jul 11, 2017
Drug: Aripiprazole Lauroxil · For: Schizophrenia
Sites: Little Rock, Arkansas; Rogers, Arkansas; Anaheim, California · 18 sites in all
- A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective DisorderCompleted
Alkermes, Inc.Industry
NCT02636842 · 47 participants · Start Dec 2015 · Primary completion Jun 2016
Drug: Aripiprazole Lauroxil · For: Schizophrenia; Schizoaffective Disorder
Sites: Cerritos, California; Lemon Grove, California; Oakland, California · 6 sites in all
- Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia EpisodeTerminated
University of California, Los AngelesAcademic, hospital or other
NCT04203056 · 15 participants · Start Dec 16, 2019 · Primary completion Oct 1, 2022
Drug: Aripiprazole Lauroxil; ARI-ORAL and 1 more · For: Schizophrenia; Schizoaffective Disorder, Depressive Type; Schizophreniform Disorder
Sites: Los Angeles, California
University of MiamiAcademic, hospital or other
NCT05662306 · 1 participants · Start Jan 23, 2024 · Primary completion Mar 3, 2025
Drug: Aripiprazole Lauroxil · For: Schizophrenia
Sites: Miami, Florida
VA Office of Research and DevelopmentFederal agency
NCT05554627 · 0 participants · Start Oct 27, 2023 · Primary completion Oct 27, 2023
Drug: Esketamine; Aripiprazole · For: Depressive Disorder, Major
Sites: Tuscaloosa, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 26 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use118
- product administration error41
- injection site pain34
- drug ineffective24
- product administered at inappropriate site22
- psychotic disorder22
- hallucination, auditory21
- therapeutic response shortened21
- akathisia20
- restlessness19
- treatment noncompliance19
- nausea17
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 39 |
| 2019 | 61 |
| 2020 | 44 |
| 2021 | 65 |
| 2022 | 35 |
| 2023 | 58 |
| 2024 | 44 |
| 2025 | 28 |
| 2026 | 24 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study.
Nasrallah HA, Weiden PJ, Walling DP, et al. · BMC Psychiatry 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
Meltzer HY, Risinger R, Nasrallah HA, et al. · J Clin Psychiatry 2015 · Multicenter Study, Randomized Controlled Trial
- Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia.
Nasrallah HA, Aquila R, Du Y, et al. · CNS Spectr 2019 · Clinical Trial, Phase III, Multicenter Study
- Initiating Aripiprazole Lauroxil: Post Hoc Analysis of Safety and Tolerability of 1-Day and 21-Day Regimens.
Sommi RW, Saklad SR, Weiden PJ, et al. · J Clin Psychiatry 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
Cameron C, Zummo J, Desai DN, et al. · Value Health 2017 · Comparative Study, Review
- Aripiprazole Lauroxil NanoCrystal ® Dispersion Technology (Aristada Initio ® ).
Ehret MJ, Davis E, Luttrell SE, et al. · Clin Schizophr Relat Psychoses 2018 · Comparative Study, Randomized Controlled Trial
Sponsor: Alkermes INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.